Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A07992 | Pages: 139 | Charts: 02 | Tables: 87 |
The global bioprocess validation market size was valued at $265.15 million in 2019 and is projected to reach $410.80 million by 2027, registering a CAGR of 5.5% from 2020 to 2027. Bioprocess validation involves a series of activities taking place over the entire production cycle of a bio-product. An important part of bioprocess validation requires the evaluation of active pharmaceutical ingredients (APIs) and possible contaminants, such as mycoplasma, bacteria, endotoxin, and others, during the development and manufacture processes of animal drugs or other biological products. Precisely, data are collected, evaluated, and documented from every stage of a specific project at all desired levels. In this way, bioprocess validation establishes the scientific evidence that a process is capable of consistently delivering quality product. As a result, effective process validation contributes significantly to assure drug quality, safety, and efficacy.
Get more information on this report : Request Sample Pages
The bioprocess validation market is positively impacted by the pandemic as many pharmaceutical and biotechnological companies use validation services for at least some of their bioprocessing. The bioprocessing sector is experiencing operational and personnel-related problems, but often these are related to increased activity. Essentially, all bioprocessing-related industrial activities are continuing largely unaffected in terms of operations and output. Many bioprocessing processes are being leveraged for the development of vaccines against coronaviruses. For instance, many companies, including developers and suppliers of services are increasing their pandemic-related R&D and manufacturing. Single-use bioreactors and other disposable components along with process automation should facilitate and optimize quality control and validation of bioprocessed vaccines and therapies. Suppliers are anticipating and planning for increased business as companies and governments start to rapidly develop and test pandemic-related vaccines.
Moreover, service providers are witnessing an upsurge in inquiries and orders mostly related to pandemic vaccine or therapeutics. Many suppliers of both equipment and services have begun increasing their activities in response to this increase and projected demand. The coronavirus pandemic has affected the global economy through three channels, direct impact on production, supply chain & market disruption, and financial impact on firms & financial markets. In addition, this pandemic has affected the production and import & export of finished goods due to shutdown in various COVID-19-affected countries. Moreover, delayed shipments & production schedules may create financial problems for companies with heavy debts.
The growth of the global bioprocess validation market is driven by stringent safety & quality regulations, increase in demand for biopharmaceuticals, and surge in demand for outsourcing bioprocess validation. In addition, increase in life science R&D expenditure is expected to fuel the market growth. However, issues related to extractables are expected to impede the market growth. On the contrary, patent expiry of bio-product is expected to present various opportunities for the market expansion.
The global bioprocess validation market is segmented on the basis of test type, process component, end user, and region. Based on test type, the market is segmented into extractables testing services, microbiological testing services, physiochemical testing services, integrity testing services, compatibility testing services, and other testing services. By process component, it is further classified into filter elements, bioreactors, and others. On the basis of end user, it is divided into contract development & manufacturing organizations and pharmaceutical & biotechnology companies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
In terms of test type, the extractables testing services segment dominated the bioprocess validation market in 2019. The large share of this segment can be attributed to the presence of regulatory mandates & guidelines regarding the testing of extractables. Moreover, increase in outsourcing of testing services by biopharmaceutical manufacturers; rise in requirement for product safety, identity, purity, and quality; and the increase in risk of product adulteration are expected to boost the bioprocess validation market growth.
[TESTTYPEGRAPH]
Get more information on this report : Request Sample Pages
By end user, the pharmaceutical & biotechnology companies segment is projected to grow at the highest CAGR of 5.8% during the forecast period, owing to increase in production of biopharmaceuticals, consistent increase in the number of impurities to be checked, stringency of standards & regulations regarding the quality, and validity of bioprocesses involved in the production.
[ENDUSERGRAPH]
Get more information on this report : Request Sample Pages
Asia-Pacific held the major share of the bioprocess validation market in 2019, and is expected to continue its dominance during the forecast period, owing to increase in biopharmaceutical manufacturing capabilities in Asia-Pacific countries, increase in demand for outsourcing bioprocess validation, rise in life science research specific to biologics, and surge in investments by pharmaceutical & biotechnology companies. Additionally, there is rise in awareness about the advantages of biopharmaceutical drugs, increase in number of CROs and Contract Development & Manufacturing Organizations, and favorable government initiatives to promote the growth of the pharmaceutical & biotechnology industries in several APAC countries.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
Comprehensive competitive analysis and profiles of the major market players, such as Cobetter Filtration Equipment Co., Ltd, Danher Corporation, Merck KGaA, Porvair Plc, Sartorius, Thermo Fisher Scientific, Inc., Meissner Filtration Products, Inc, Toxikon Corporation, Almac Group, and Biozeen, are provided in this report.
Key benefits for stakeholders
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.1.Key benefits for stakeholders
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Stringent Safety & Quality Regulations
3.5.1.2.Increasing Demand for Outsourcing Bioprocess Validation
3.5.2.Restraints
3.5.2.1.Issues Related to Extractables & Leachables
3.5.3.Opportunity
3.5.3.1.Patent Expiry of Molecules
3.5.4.Impact Analysis
3.6.Impact of COVID-19 on Bioprocess Validation Market
CHAPTER 4:BIOPROCESS VALIDATION, BY TEST TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Extractables Testing Services
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Microbiological Testing Services
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Physiochemical Testing Services
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Integrity Testing Services
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Chemical Compatibility Testing
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Other Testing
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
CHAPTER 5:BIOPROCESS VALIDATION, BY PROCESS COMPONENT
5.1.Overview
5.1.1.Market size and forecast
5.2.Filter Elements
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Bioreactors
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Other Process Component
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:BIOPROCESS VALIDATION, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Pharmaceutical and biotechnology companies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Contract development & manufacturing organizations
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:GLOBAL BIOPROCESS VALIDATION MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America bioprocess validation market , by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. bioprocess validation market, by test type
7.2.2.1.2.U.S bioprocess validation market, by process component
7.2.2.1.3.U.S. bioprocess validation market, by end user
7.2.2.2.Canada
7.2.2.2.1.Canada bioprocess validation market, By Test Type
7.2.2.2.2.Canada bioprocess validation market, by process component
7.2.2.2.3.Canada bioprocess validation market, by end user
7.2.2.3.Mexico
7.2.2.3.1.Mexico bioprocess validation market, By Test Type
7.2.2.3.2.Mexico bioprocess validation market, by process component
7.2.2.3.3.Mexico bioprocess validation market, by end user
7.2.3.North America bioprocess validation market, By Test Type
7.2.4.North America bioprocess validation market , by process component
7.2.5.North America bioprocess validation market , by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe bioprocess validation market , by country
7.3.2.1.UK bioprocess validation market, By Test Type
7.3.2.1.1.UK bioprocess validation market, By Test Type
7.3.2.1.2.UK bioprocess validation market, by process component
7.3.2.1.3.UK bioprocess validation market, by end user
7.3.2.2.Germany
7.3.2.2.1.Germany bioprocess validation market, By Test Type
7.3.2.2.2.Germany bioprocess validation market, by process component
7.3.2.2.3.Germany bioprocess validation market, by end user
7.3.2.3.France
7.3.2.3.1.France bioprocess validation market, By Test Type
7.3.2.3.2.France bioprocess validation market, by process component
7.3.2.3.3.France bioprocess validation market, by end user
7.3.2.4.Italy
7.3.2.4.1.Italy bioprocess validation market, By Test Type
7.3.2.4.2.Italy bioprocess validation market, by process component
7.3.2.4.3.Italy bioprocess validation market, by end user
7.3.2.5.Spain
7.3.2.5.1.Spain bioprocess validation market, By Test Type
7.3.2.5.2.Spain bioprocess validation market, by process component
7.3.2.5.3.Spain bioprocess validation market, by end user
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe bioprocess validation market, By Test Type
7.3.2.6.2.Rest of Europe bioprocess validation market, by process component
7.3.2.6.3.Rest of Europe bioprocess validation market, by end user
7.3.3.Europe bioprocess validation market , By Test Type
7.3.4.Europe bioprocess validation market , by process component
7.3.5.Europe bioprocess validation market , by end user
Asia-pacific
7.3.6.Key market trends, growth factors, and opportunities
7.3.7.Asia-Pacific bioprocess validation market, by country
7.3.7.1.Japan
7.3.7.1.1.Japan bioprocess validation market, By Test Type
7.3.7.1.2.Japan bioprocess validation market, by process component
7.3.7.1.3.Japan bioprocess validation market, by end user
7.3.7.2.China
7.3.7.2.1.China bioprocess validation market, By Test Type
7.3.7.2.2.China bioprocess validation market, by process component
7.3.7.2.3.China bioprocess validation market, by end user
7.3.7.3.Australia
7.3.7.3.1..Australia bioprocess validation market, By Test Type
7.3.7.3.2.Australia bioprocess validation market, by process component
7.3.7.3.3.Australia bioprocess validation market, by end user
7.3.7.4.South Korea
7.3.7.4.1.. South Korea bioprocess validation market, By Test Type
7.3.7.4.2.South Korea bioprocess validation market, by process component
7.3.7.4.3.South Korea bioprocess validation market, by end user
7.3.7.5.India
7.3.7.5.1.India bioprocess validation market, By Test Type
7.3.7.5.2.India bioprocess validation market, by process component
7.3.7.5.3.India bioprocess validation market, by end user
7.3.7.6.Rest of Asia-Pacific
7.3.7.6.1.Rest of Asia-Pacific bioprocess validation market, By Test Type
7.3.7.6.2.Rest of Asia-Pacific bioprocess validation market, by process component
7.3.7.6.3.Rest of Asia-Pacific bioprocess validation market, by end user
7.3.8.Asia-Pacific bioprocess validation market , By Test Type
7.3.9.Asia-Pacific bioprocess validation market , by process component
7.3.10.Asia-Pacific bioprocess validation market , by end user
7.4.LAMEA
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.LAMEA bioprocess validation market , by country
7.4.2.1.Latin America
7.4.2.1.1.Latin America bioprocess validation market, By Test Type
7.4.2.1.2.Latin America bioprocess validation market, by process component
7.4.2.1.3.Latin America bioprocess validation market, by end user
7.4.2.2.Middle East and Africa
7.4.2.2.1.Middle East and Africa bioprocess validation market, By Test Type
7.4.2.2.2.Middle East and Africa bioprocess validation market, by process component
7.4.2.2.3.Middle East and Africa bioprocess validation market, by end user
7.4.3.LAMEA bioprocess validation market , By Test Type
7.4.4.LAMEA bioprocess validation market , by process component
7.4.5.LAMEA bioprocess validation market , by end user
CHAPTER 8:COMPANY PROFILES
8.1.Almac Group
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments
8.2.Bangalore Biotech Labs Pvt Ltd (Biozeen)
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.3.Cobetter Filtration Equipment Co., Ltd
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.4.Danher Corporation.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Meissner Filtration Products, Inc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.6.Merck KGaA
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.Porvair Plc
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance.
8.8.Sartorius Ag
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Toxikon Corporation
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.10.Thermo Fisher Scientific, Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.BIOPROCESS VALIDATION MARKET, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 02.BIOPROCESS VALIDATION MARKET REVENUE, BY EXTRACTABLES/LEACHABLES TESTING SERVICES, 2019–2027 ($MILLION)
TABLE 03.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY MICROBIOLOGICAL TESTING SERVICES, 2019–2027 ($MILLION)
TABLE 04.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY PHYSIOCHEMICAL TESTING SERVICES, 2019–2027 ($MILLION)
TABLE 05.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY INTEGRITY TESTING SERVICES, 2019–2027 ($MILLION)
TABLE 06.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY CHEMICAL COMPATIBILITY TESTING, 2019–2027 ($MILLION)
TABLE 07.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY OTHER TESTING, 2019–2027 ($MILLION)
TABLE 08.BIOPROCESS VALIDATION MARKET, BY PROCESS COMPONENT, 2019–2027 ($MILLION)
TABLE 09.BIOPROCESS VALIDATION MARKET REVENUE, BY FILTER ELEMENTS, 2019–2027 ($MILLION)
TABLE 10.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY BIOREACTORS, 2019–2027 ($MILLION)
TABLE 11.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY OTHER PROCESS COMPONEN, 2019–2027 ($MILLION)
TABLE 12.BIOPROCESS VALIDATION MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 13.BIOPROCESS VALIDATION MARKET REVENUE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2019–2027 ($MILLION)
TABLE 14.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, 2019–2027 ($MILLION)
TABLE 15.GLOBAL BIOPROCESS VALIDATION MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 16.NORTH AMERICA BIOPROCESS VALIDATION MARKET , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 17.U.S. BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 18.U.S. BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 19.U.S. BIOPROCESS VALIDATION MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 20.CANADA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 21.CANADA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 22.CANADA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 23.MEXICO BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 24.MEXICO BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 25.MEXICO BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 26.NORTH AMERICA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 27.NORTH AMERICA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 28.NORTH AMERICA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 29.EUROPE BIOPROCESS VALIDATION MARKET , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 30.UK BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 31.UK BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 32.UK BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 33.GERMANY BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 34.GERMANY BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 35.GERMANY BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 36.FRANCE BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 37.FRANCE BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 38.FRANCE BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 39.ITALY BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 40.ITALY BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 41.ITALY BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 42.SPAIN BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 43.SPAIN BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 44.SPAIN BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 45.REST OF EUROPE BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 46.REST OF EUROPE BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 47.REST OF EUROPE BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 48.EUROPE BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 49.EUROPE BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 50.EUROPE BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 51.ASIA-PACIFIC BIOPROCESS VALIDATION MARKET , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 52.JAPAN BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 53.JAPAN BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 54.JAPAN BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 55.CHINA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 56.CHINA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 57.CHINA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 58.AUSTRALIA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 59.AUSTRALIA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 60.AUSTRALIA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 61.SOUTH KOREA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 62.SOUTH KOREA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 63.SOUTH KOREA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 64.INDIA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 65.INDIA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 66.INDIA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 70.ASIA-PACIFIC BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 71.ASIA-PACIFIC BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 72.ASIA-PACIFIC BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 73.LAMEA BIOPROCESS VALIDATION MARKET , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 74.LATIN AMERICA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 75.LATIN AMERICA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 76.LATIN AMERICA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 77.MIDDLE EAST AND AFRICA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 78.MIDDLE EAST AND AFRICA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 79.MIDDLE EAST AND AFRICA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 80.LAMEA BIOPROCESS VALIDATION MARKET , BY TEST TYPE, 2019-2027 ($MILLION)
TABLE 81.LAMEA BIOPROCESS VALIDATION MARKET , BY PROCESS COMPONENT, 2019-2027 ($MILLION)
TABLE 82.LAMEA BIOPROCESS VALIDATION MARKET , BY END USER, 2019-2027 ($MILLION)
TABLE 83.ALMAC: COMPANY SNAPSHOT
TABLE 84.ALMAC: OPERATING SEGMENTS
TABLE 85.ALMAC: PRODUCT PORTFOLIO
TABLE 86.BIOZEEN: COMPANY SNAPSHOT
TABLE 87.BIOZEEN: OPERATING SEGMENTS
TABLE 88.BIOZEEN: PRODUCT PORTFOLIO
TABLE 89.COBETTER: COMPANY SNAPSHOT
TABLE 90.COBETTER: OPERATING SEGMENTS
TABLE 91.COBETTER: PRODUCT PORTFOLIO
TABLE 92.DANAHER: COMPANY SNAPSHOT
TABLE 93.DANAHER: OPERATING SEGMENTS
TABLE 94.DANAHER: PRODUCT PORTFOLIO
TABLE 95.DANAHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 96.MEISSNER: COMPANY SNAPSHOT
TABLE 97.MEISSNER: OPERATING SEGMENTS
TABLE 98.MEISSNER: PRODUCT PORTFOLIO
TABLE 99.MERCK: COMPANY SNAPSHOT
TABLE 100.MERCK: OPERATING SEGMENTS
TABLE 101.MERCK: PRODUCT PORTFOLIO
TABLE 102.PORVAIR: COMPANY SNAPSHOT
TABLE 103.PORVAIR: OPERATING SEGMENTS
TABLE 104.PORVAIR: PRODUCT PORTFOLIO
TABLE 105.SARTORIUS: COMPANY SNAPSHOT
TABLE 106.SARTORIUS: OPERATING BUSINESS SEGMENTS
TABLE 107.SARTORIUS: PRODUCT PORTFOLIO
TABLE 108.TOXIKON: COMPANY SNAPSHOT
TABLE 109.TOXIKON: PRODUCT SEGMENTS
TABLE 110.TOXIKON: PRODUCT PORTFOLIO
TABLE 111.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 112.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENTS
TABLE 113.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.BIOPROCESS VALIDATION MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGANING POWER OF SUPPLIER
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.HIGH THREAT OF NEW ENTRANT
FIGURE 10.MODERATE THREAT OF SUBSTITUTION
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR EXTRACTABLES/LEACHABLES TESTING SERVICES BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR MICROBIOLOGICAL TESTING SERVICES BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR PHYSIOCHEMICAL TESTING SERVICES BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR INTEGRITY TESTING SERVICES BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR CHEMICAL COMPATIBILITY TESTING BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR OTHER TESTING BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR FILTER ELEMENTS BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR BIOREACTORS BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR OTHER PROCESS COMPONEN BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIESBY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF BIOPROCESS VALIDATION MARKET, FOR CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.DANAHER: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 26.DANAHER: REVENUE SHARE BY GEOGRAPHY, 2019 (%)
FIGURE 27.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 29.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 30.PORVAIR: NET SALES, 2017–2019 ($MILLION)
FIGURE 31.PORVAIR: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 32.PORVAIR: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 33.SARTORIUS: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.SARTORIUS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 35.SARTORIUS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 01.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 01.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 02.THERMO FISHER SCIENTIFIC. REVENUE SHARE BY REGION, 2019 (%)